Drug Trial Radar · NCT05896254
Study of MAR001 in Adults With Metabolic Dysfunction
Last checked: Nov 19, 2026Latest source record: Nov 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
55
Actual
Start
Jul 22, 2023
Primary completion
Dec 13, 2024
Study completion Dec 13, 2024
Sponsor
- Lead sponsor
- Marea TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jun 9, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and tolerability of multiple doses of MAR001in adult volunteers with metabolic dysfunction.
Conditions
- Hypertriglyceridemia
Interventions
MAR001Drug
Subcutaneous injection
PlaceboDrug
Subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability of MAR001Time frame: 12 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Brisbane Site
Brisbane, Australia
Melbourne Site
Melbourne, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.